Conditions: Atrial Fibrillation Atrial Flutter
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20976
Healthy volunteers: no

Brief summary:
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: warfarin intervention 2: apixaban
Intervention descriptions: intervention 1: Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0) intervention 2: Oral tablets, 5.0 mg or 2.5 mg, twice daily

Protocol document: